NMPA Approves Innovative Intrasaccular Aneurysm Embolization System on 29 June 2026

Summary

On 29 June 2026, the National Medical Products Administration (NMPA) approved the registration of the innovative product "Intrasaccular Aneurysm Embolization System" (动脉瘤瘤内栓塞系统) developed by Beijing Taijie Weiye Technology Co., Ltd.

• The device is intended for endovascular treatment of specific unruptured, wide-necked, bifurcation intracranial aneurysms.
• It features a two-dimensional disc-shaped structure and a recessed bottom design, and generally does not require permanent post-operative dual antiplatelet therapy, which is expected to reduce bleeding risk.
• The approval is a useful reference for companies active in neurointervention, particularly in relation to innovative medical device applications, product design and clinical evaluation strategy.

Full Translation of the Original NMPA Notice

Recently, the National Medical Products Administration approved the registration application for the innovative product "Intrasaccular Aneurysm Embolization System" of Beijing Taijie Weiye Technology Co., Ltd.

The product consists of an implant, a delivery system and an introducer sheath. It is intended for endovascular treatment of small- and medium-sized saccular, wide-necked, unruptured bifurcation intracranial aneurysms in adult patients, where the aneurysm diameter is 3 mm to 15 mm and the neck size is ≥4 mm, or the dome-to-neck ratio is >1 and <2.

The product adopts a two-dimensional disc-shaped structure and a recessed bottom design. The implant is located entirely within the aneurysm cavity and does not cover the parent artery. Permanent dual antiplatelet therapy is generally not required after the procedure, and the product is expected to reduce the risk of associated bleeding.

The drug regulatory authority will strengthen post-market surveillance of this product to protect the safety of patients using the device.

Source and Applicability

• Source organisation: NMPA Medical Devices
• Original date: 29 June 2026
• Publication date on this site: 9 July 2026, 15:00
• Source link: https://www.nmpa.gov.cn/zhuanti/cxylqx/cxylqxlm/20260629163806180.html

This article was compiled from publicly available information published by NMPA Medical Devices. Specific requirements are subject to the latest official publications of the regulatory authority.

AIMEILI Regulatory Interpretation

Commentary from the AIMEILI Regulatory Department:

The NMPA approval of the Intrasaccular Aneurysm Embolization System as an innovative medical device once again demonstrates that the Chinese regulator grants priority review to devices that address unmet clinical needs and offer significant clinical advantages. Companies planning to register innovative medical devices in China should pay particular attention to the following points.

1. Registration pathway and classification

The product was approved as an innovative medical device, which indicates that companies whose products feature novel designs or significant clinical advantages should apply for innovative medical device designation as early as possible. Classification should be assessed against the Medical Device Classification Catalogue and the Special Review Procedure for Innovative Medical Devices, and it should be clarified whether the product is a Class III device.

2. Technical documentation requirements

The technical description of this product (two-dimensional disc-shaped structure, recessed bottom design, no permanent dual antiplatelet therapy) reflects a detailed design rationale and a clear clinical value proposition. When preparing technical documentation, companies should describe in detail the product's structural composition, mechanism of action, material characteristics and the differences from similar products already on the market. Performance verification should include in vitro simulation and animal studies to support clinical safety and effectiveness.

3. Clinical evaluation strategy

The product is indicated for aneurysms of specific size and morphology, so the clinical evaluation must clearly define the target population. Companies may use a clinical trial (designed with a single-arm objective performance criterion or as a randomised controlled trial) or a comparison with an approved equivalent device, but should note the particular characteristics of wide-necked and bifurcation sites. This approval indicates that a well-designed clinical study combined with clearly demonstrated clinical benefit (for example, avoiding dual antiplatelet therapy and reducing bleeding risk) can support a successful review.

4. Labeling, instructions for use and post-market surveillance

The fact that permanent dual antiplatelet therapy is not required after the procedure is an important promotional point for this product; this should be clearly stated in the label and be consistent with the instructions for use. The NMPA has emphasised strengthened post-market surveillance, so companies need to establish robust post-market clinical follow-up and adverse event reporting systems and to collect long-term safety data on a continuous basis, particularly on bleeding risk and embolisation performance.

5. Quality management system requirements

Following approval of an innovative medical device, the company should ensure that its manufacturing quality management system complies with the Good Manufacturing Practice for Medical Devices (GMP), in particular with respect to the manufacture, sterilisation, traceability and complaint handling of implantable devices. The NMPA may conduct unannounced inspections of manufacturing sites, so documentation should be inspection-ready at all times.

In summary, this approval provides a valuable reference for companies in the neurointervention field. Key elements of the registration strategy are obtaining innovative device designation at an early stage, providing a clear chain of clinical evidence and highlighting differentiating advantages. At the same time, companies must pay attention to post-market surveillance requirements and ensure compliance throughout the product lifecycle.

Business Impact for Medical Device Manufacturers

From the perspective of international medical device registration practice, information of this kind published by NMPA Medical Devices should not be read simply as general news. Companies should first determine whether it constitutes regulatory policy, guidance or standards, product approval, recall or safety information, quality system information or post-market surveillance information, because each category triggers different internal actions. Where a company is running a registration project in a related market, the update should be added to the target-market regulatory tracking table to confirm whether it affects product classification, the registration pathway, the applicant entity, local authorised representative responsibilities or certificate maintenance arrangements.

For Chinese medical device manufacturers, the direct impact of the NMPA approval of the innovative Intrasaccular Aneurysm Embolization System on 29 June 2026 is typically seen in documentation consistency and evidence chain management. Companies should review their existing technical files, risk management reports, performance verification data, clinical evaluation or clinical evidence, labels and instructions for use, quality system certificates and post-market surveillance documents to confirm that these still support the latest regulatory expectations in the target markets. Where the information concerns a safety notice, recall, product approval or regulatory meeting, companies should also assess whether regulators are likely to focus on similar products, similar technology routes or similar risk points.

At the operational level, AIMEILI recommends that companies establish three actions:

• Record the official source link, publication date, applicable product scope and potentially affected areas in the regulatory tracking log.
• Have regulatory affairs, quality, R&D and sales jointly determine whether labels, instructions for use, clinical evaluation, risk management or test reports need to be updated.
• Where the product is already marketed locally or a registration application has already been submitted, assess in parallel whether the local authorised representative, importer, distributor and after-sales team need to take communication, change notification, supplementary clarification or post-market monitoring measures.

The value of this kind of news lies not simply in knowing what the regulator has published, but in converting public information into executable compliance actions. For companies preparing multi-country registrations, particular attention should be paid to the boundaries of documentation reuse across markets: the same set of CE, FDA, NMPA, ISO 13485 or MDSAP documentation may serve as core evidence in one country but require supplementary localised explanations, translated labels, authorised representative documentation or a post-market maintenance plan in another. AIMEILI recommends that companies carry out a brief documentation gap review after every significant regulatory update to avoid difficulties at the later deficiency response, change notification or certificate renewal stage.

Frequently Asked Questions

Can the NMPA approval of the innovative Intrasaccular Aneurysm Embolization System on 29 June 2026 be used directly as the basis for a regulatory submission?

No. This article is intended for preliminary understanding and project assessment only; a formal submission must still be based on the latest requirements of the regulatory authority in the target country, the conclusion on product classification and the company's own documentation status.

What should a company do first after seeing an update of this kind?

Conduct a documentation gap assessment first, to confirm whether the update affects the registration pathway, technical documentation, labeling, the quality management system or post-market maintenance obligations.

Related Updates

• 1 July 2026: Implantable Cardiac Event Monitor approved for marketing
• 3 July 2026: Medical Device Regulatory Research Project Report Meeting held in Yantai, Shandong
• 6 July 2026: Launch meeting of the NMPA Regulatory Science Innovation Research Base and Medical Device Innovation Seminar held in Beijing
• 30 June 2026: NMPA publishes interpretation of the Guiding Principles for Classification Determination of Brain-Computer Interface Medical Device Products
• 17 June 2026: Health Canada publishes Phase 2 amendments to the modernisation of medical device establishment licences
• 7 July 2026: FDA announces a public meeting on medical device user fee reauthorisation

Content Review and Scope of Application

• Content author: AIMEILI Regulatory Editorial Team
• Professional review: AIMEILI International Medical Device Registration Project Team
• Source principles: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.
• Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the regulatory authority in the target country, testing conclusions or legal advice.

Need to Assess Your Registration Pathway?

Please provide the product name, intended use, target markets and the documentation you currently hold, and AIMEILI can assist in determining the registration pathway, documentation gaps and compliance risks. Contact AIMEILI to discuss your project.